Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (FIGO stage III or IV).
- Your oncology team recommends starting chemotherapy before surgery (neoadjuvant treatment).
- Recent tests show your kidneys, liver, bone marrow, and nervous system are functioning well enough for treatment.
- You have no serious active infection or uncontrolled medical problem within 4 weeks of starting; if you had COVID-19, you must be 14 days past symptoms or the positive test.
- You haven’t had IMNN-001 before, and you can stop tumor-related hormonal therapy at least 1 week before the first dose (hormone replacement is allowed).
- If you can become pregnant: you must have a negative pregnancy test within 14 days, use effective birth control, and stop breastfeeding before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests a new combination of drugs given before surgery to shrink advanced ovarian cancer, which may make it easier to remove and improve outcomes. It includes an immunotherapy drug that helps your immune system fight cancer, along with standard chemotherapy.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.